Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New perspectives in angiotensin system control

P B Timmermans1, P C Wong, A T Chiu

  • 1Du Pont Merck Pharmaceutical Company, Wilmington, DE 19880-0400.

Journal of Human Hypertension
|August 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacological properties of angiotensin II receptor antagonists.

The Canadian journal of cardiology·1999
Same author

Combined spinal-epidural analgesia in the management of labouring parturients with mitral stenosis.

Anaesthesia and intensive care·1999
Same author

Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics.

Hypertension research : official journal of the Japanese Society of Hypertension·1999
Same author

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors.

Proceedings of the National Academy of Sciences of the United States of America·1999
Same author

Rationale, background, and design of the randomized angiotensin receptor antagonist--angiotensin-converting enzyme inhibitor study (RAAS).

The American journal of cardiology·1996
Same author

Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy.

Journal of medicinal chemistry·1996

Losartan, an angiotensin II receptor antagonist, effectively blocks AT1 receptor actions, demonstrating significant therapeutic potential in managing hypertension and related cardiovascular conditions. Further research into AT2 receptor roles continues to evolve our understanding of the angiotensin system.

Area of Science:

  • Cardiovascular Pharmacology
  • Endocrinology
  • Molecular Biology

Background:

  • The angiotensin system regulates physiological functions via angiotensin II.
  • Angiotensin II exerts effects through specific receptors, including AT1 and AT2.
  • Non-peptide receptor antagonists have enabled detailed study of angiotensin II actions.

Purpose of the Study:

  • To investigate the effects of selective angiotensin II receptor antagonists.
  • To elucidate the roles of AT1 and AT2 receptors in various physiological processes.
  • To explore the therapeutic potential of angiotensin II receptor blockade.

Main Methods:

  • Administration of selective AT1 (losartan) and AT2 (PD123177) receptor antagonists.
  • Evaluation of effects on blood pressure in hypertensive models.

Related Experiment Videos

  • Assessment of cardiac hypertrophy and vascular injury responses.
  • Cloning of AT1 receptor subtypes from rat tissues.

    • Main Results:

    • Losartan effectively blocks virtually all known angiotensin II effects mediated by AT1 receptors.
    • AT1 receptor blockade with losartan lowers blood pressure in hypertension, reduces cardiac hypertrophy, and improves cardiac failure hemodynamics.
    • Losartan mitigates the intimal response to vascular injury.
    • AT2 receptor localization in the brain and fetal tissue suggests distinct functions, though roles remain under investigation.

    Conclusions:

    • Selective AT1 receptor blockade with losartan offers significant therapeutic benefits for hypertension and cardiovascular diseases.
    • The discovery of receptor antagonists has greatly advanced the understanding of the angiotensin system.
    • Future therapeutic strategies may involve more specifically targeted agents based on receptor subtype cloning.